Home > Formulary : Adult > Recent Decisions > 2015 >
Decisions 14th July 2015
At the meeting that took place on 14th July, the following decisions were agreed:
New Drug Requests
Approved
Palonosetron (TLS Red)
- Approved for inclusion onto the formulary for adults who are being treated for Hodgkin’s lymphoma. NBT only.
Tocilizumab (subcutaneous) (TLS Red)
- The subcutaneous preparation was approved for inclusion onto the formulary for moderate to severe rheumatoid arthritis in accordance with NICE TA 247
Brinzolamide & Brimonidine (Simbrinza®) (TLS Blue)
- Approved for inclusion onto the formulary for glaucoma patients in whom compliance is an issue.
Shared Care Protocols/TLS Change in Status
Rifaximin
- The JFG approved the SCP for amber 3 months.
Hydroxycarbamide
- The JFG approved the updated SCP.
Dabigatran
- The JFG approved the SCP for the treatment and prevention of DVT/PE.
Apixaban
- The JFG approved the SCP for the treatment and prevention of DVT/PE.
Rivaroxaban
- The JFG approved the SCP for ACS.